Clinical Trials & Results

Search or filter the listing below to find a trial or results of a completed trial.

View Actively Recruiting Clinical Trials

Click here to see trials currently recruiting participants

Filter

Health Condition

Toggle

Study Status

Toggle

Age group

Toggle

Gender

Toggle

Phase

Toggle

Study Types

Toggle

All Results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

Clear Filters

Efficacy and Safety of Fremanezumab for Migraine in Patients With Major Depressive Disorder

headache-icon.png
Condition(s):
Migraine | Major Depressive Disorder
Status:
Completed
Requirements:
18 Years to 70 Years
Interventions:
Drug: Fremanezumab | Drug: Placebo
Learn more Primary objectives: The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult patients with migraine and major depressive disorder (MDD). Secondary objectives: The secondary objectives are to evaluate the efficacy of monthly 225 mg sc of fremanezumab in adult patients with migraine and MDD on the reduction of MDD symptoms, responder rates in monthly migraine days, improving quality of life, improving disability, and the safety and tolerability of monthly 225 mg sc and quarterly 675 mg sc fremanezumab in adult patients with migraine and MDD. The total duration of patient participation in the study is planned to be approximately 28 weeks.